Navidad CF, Chávez MMA

Language: Spanish
References: 15
Page: 87-93
PDF size: 450.15 Kb.

ABSTRACT

Background. The Human Epidermal growth factor Receptor 2 (HER2) is amplified in approximately 15 to 20% of the breast carcinoma cases. The official name of this receptor proposed by the Nomenclature Committee is ERBB2 gene.
Methods. A comparative study was conducted to validate the immunohistochemistry, which examined 25 samples in the Carpermor International Reference Laboratory in parallel to the Specialty Laboratory, according to the guide of recommendations for the validation test HER2 by the College of American Pathologists (CAP), and the American Society of Clinical Oncology (ASCO).
Results. Our results are reproducible according to the reference values published in the recommendations Guide published by the CAP and ASCO, which was obtained as validating the immunohistochemistry test for Human Epidermal growth factor Receptor 2 (HER2).
Conclusions. The overexpression of HER2 is associated with worse prognosis in patients with newly diagnosed breast cancer not receiving adjuvant chemotherapy. More important are the results showing that therapeutic agents that target the HER2s are very efficient in the treatment of metastatic and adjuvant therapies. Taken together, the clinical results indicate that HER2 is a useful factor in therapeutic decision-making in patients with breast cancer, and emphasize the importance of thorough evaluation of this test.

REFERENCES

1. Wolff A, Hammond E, et al. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Special Article. Arch Pathol Lab Med 2007;131:18-43.

2. David J. Dabbs. Diagnostic Inmmunohistochemistry. 2a ed. USA:Churchill Livingtone, 2002. pp: 699-745.

3. Larry W. Clark, et al. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline. NCCLS. 2002;22:14.

4. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.

5. Bang Y-J, Van Cutsem E, Feyereislova A, et al. For the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.

6. Slamon DJ, Clark GM, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-27/neu oncogene. Science 1987;235:177-182.

7. Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004;24:201-209.

8. Villman K, Sjostrom J, Heikkila R, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol 2006;45:590-596.

9. Hayes DF, Thor A, Dressier L, et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 2006;24:5S.

10. Joensuu H, Kellokumpu- Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine whit or without trastuzumab for breas cancer. N Engl J Med 2006;354:809-820.

11. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxoribicin and cyclophosphamide followed by docetaxel (ACT) with doxoribicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) whit docetaxel, carboplatin and trastuzumab (TCH) in Her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5.

12. Geyer CE, Bryant JL, et al. Four year update of cardiacac dysfunction on NSABP B-31: A randomized trial for AC>paclitaxel vs AC>paclitaxel whit trastuzumab in HER2 positive, node positive operable breast cancer. J Clin Oncol 2006;24:23S.

13. Ellis IO, et al. Best pactice No 176. Updated recommendatons for Her2 testing in the UK. J Clin Pathol 2004;57:233-237.

14. Dal Lago L, Durbecq V, et al. Correction for chromosome 17 is critical for determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579.

15. Persons DL, Tubbs RR, et al. HER-2 fluorescence in situ hybridization: Results from the survey program of the College of American Pathologists. Arch Pathol Lab med 2006;130:325-331.